Avantor Inc. recently delivered a presentation at the RBC Capital Markets 2025 Global Healthcare Conference, highlighting its business segments and financial performance. The company reported that its Laboratory Solutions segment accounts for approximately two-thirds of its revenue, with a margin of 13.0%. This segment offers a comprehensive portfolio of laboratory consumables, equipment, services, and digital solutions. The Bioscience Production segment makes up about one-third of the revenue, with a higher margin of 25.7%. Avantor emphasized its strong foundation in bioscience production, providing mission-critical, high-purity materials and solutions. The company's bioprocessing offerings cover the full production workflow, with specific revenue contributions from process ingredients, controlled environment consumables, and downstream process optimization solutions. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.